Back to Agenda
Politics, Policy and the First Amendment: What to expect from Capitol Hill, HHS, FDA and the Courts during the Second Term of the Obama Administration
Session Chair(s)
David L. Cram, PharmD
Director, Regional Account Medical Lead
Takeda, United States
Natalie Gearhart, PharmD
Associate Director, External Engagement Strategy, Medical Affairs
Johnson and Johnson, United States
At the conclusion of this session, participants shoudl be able to: -Discuss recent and important developments surrounding the health care environment important to Medical Communication, Medical Science Liaison, and Medical Writing professionals -Identify major developments on "scientific exchange" related to industry and PhRMA petitions before the FDA -Recognize the importance of recent judicial opinions on FDA regulation of off-label communications, especially U.S. v. Caronia reversing criminal conviction on a pharma employee -Summarize the HHS rules implementing the "Sunshine" provisions on the Affordable Care Act -Discuss legislative developments related to HHS, FDA, the Affordable Care Act, and the deductibility of communication and marketing costs by industry
Speaker(s)
Keynote Presenter
John Kamp
Coalition For Healthcare Communication (CHC), United States
Washington Counsel
Have an account?